DPP4 and type 2 diabetes mellitus: These aspects can be particularly relevant taking into account that, although some meta-analysis indicate that inhibition of DPP4a with gliptins may decrease the risk of HF and other adverse cardiovascular events in T2DM patients [47-49], it has been recently reported that DPP4 inhibition with saxagliptin is associated with increased risk of hospitalization for HF in T2DM patients [50].